NURO - NeuroMetrix shares surge after 60% rise in Q2 topline

NeuroMetrix shares soar ([[NURO]] +50.1%) after the company reported an over 60% rise in second-quarter revenue, helped by the strength in its DPNCheck and Quell businesses.The company brought in revenue of $2.2M in the quarter, compared to $1.4M in the same-period last year.NeuroMetrix's net loss during the period narrowed to $532K, or $0.13 per share, compared to a net loss of $852K, or $0.28 per share, last year.The company also highlighted that it expects to advance its Quell fibromyalgia program towards a commercial launch in 2022.Operating expenses in the quarter was $2.2M versus $1.7M in Q2 2020.However, the company also said that the quarterly results were adversely affected by a pandemic-related decline in customer orders.As of June 30 2021, the company had cash and cash equivalents of $8.36M vs $5.23M at the end of last year.Previously (July 22): NeuroMetrix reports Q2 results.

For further details see:

NeuroMetrix shares surge after 60% rise in Q2 topline